BenevolentAI SPAC Presentation Deck

Growing number of platform-generated programmes moving into clinical phases Disease Area Atopic Dermatitis (PanTrk inhibitor) Ulcerative Colitis (PDE10 Inhibitor) Amyotrophic Lateral Sclerosis Inflammatory Bowel Disease Glioblastoma Multiforme CNS Diseases Nonalcoholic Steatohepatitis (NASH) Oncology Antiviral Nonalcoholic Steatohepatitis (NASH) Oncology Oncology Chronic Kidney Disease Idiopathic Pulmonary Fibrosis 10+ Early Discovery Programmes (Multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others) Target ID Hit to Lead AstraZeneca AstraZeneca Lead Opt Preclinical Phase I start in early 2023 Clinical Source: (1) GlobalData, Epidemiology forecasts 2021, Atopic Dermatitis (7MM), IBD (8MM), ALS (8MM), GBM (7MM), NASH (7MM), CKD (7MM), IPF (7MM); 7MM = 7 major markets (US, JP, EU5); 8MM = US, JP, EUS+ Canada; (2) Evaluate Pharma, Current Worldwide Market Size (data pull 22nd Sept 2021) Atopic Dermatitis, IBD, ALS, GBM, NASH, CKD, IPF Commercial Highlights • All Pipeline assets generated from Benevolent Platform™ • Broad therapy area coverage given disease agnostic approach • Mix of Best in class, First in class and novel indications • Potential for rapid scaling and expansion into new modalities Existing pipeline alone addresses prevalent patient base* of >263m and current market opportunity >$30bn (2) Benevolent 21

View entire presentation